Liquid biopsy is a non-invasive diagnostic method that detects circulating tumor DNA (ctDNA) in blood samples to identify the presence of cancer at an early stage.
Traditional diagnostic methods like biopsies are invasive, expensive, and time-consuming. Liquid biopsy addresses these issues by providing a less invasive alternative for early detection of cancer.
The technology involves collecting a small volume of blood, isolating ctDNA from it, and analyzing for specific genetic mutations or alterations indicative of cancer. This process can be performed using various molecular biology techniques such as next-generation sequencing (NGS) and digital PCR.
The manufacturing process involves the development of reagents, consumables, and analytical tools necessary for ctDNA isolation and analysis. This includes the use of advanced sequencing technologies and bioinformatics software to interpret results.
Samples are collected using blood draw equipment, followed by processing in a laboratory setting where ctDNA is isolated and analyzed using NGS or other molecular techniques. The entire process requires specialized personnel with expertise in molecular biology and genomics.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.